KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vir Biotechnology (VIR) FCF Margin (2018 - 2025)

Vir Biotechnology (VIR) has disclosed FCF Margin for 8 consecutive years, with 40.93% as the latest value for Q4 2025.

  • Quarterly FCF Margin rose 68341.0% to 40.93% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 578.52% through Dec 2025, up 7394.0% year-over-year, with the annual reading at 578.52% for FY2025, 3283.0% up from the prior year.
  • FCF Margin hit 40.93% in Q4 2025 for Vir Biotechnology, up from 69952.92% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 2312.48% in Q2 2022 to a low of 69952.92% in Q3 2025.
  • Historically, FCF Margin has averaged 5655.38% across 5 years, with a median of 433.64% in 2023.
  • Biggest five-year swings in FCF Margin: soared 794723bps in 2024 and later crashed -6263157bps in 2025.
  • Year by year, FCF Margin stood at 0.66% in 2021, then soared by 7005bps to 45.64% in 2022, then plummeted by -1529bps to 652.06% in 2023, then dropped by -11bps to 724.34% in 2024, then soared by 94bps to 40.93% in 2025.
  • Business Quant data shows FCF Margin for VIR at 40.93% in Q4 2025, 69952.92% in Q3 2025, and 10111.78% in Q2 2025.